Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat in Resistant Hypertension
NCT06168409Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of baxdrostat in resistant hypertension (RH), sponsored by AstraZeneca. Started Mar 2024; status: completed.
02
Drugs
baxdrostat
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT06168409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06168409.